Neil Clark & Dr Bill Love of Destiny Pharma: World leading scientists to present landmark data on it's clinical asset NTCD-M3

Justin Waite
Vox Markets Podcast
09:11, 13th May 2022

AudioBoom Player

If you find this podcast useful please give it a rating and review on iTunes by clicking here


Neil Clark, CEO & Dr Bill Love, Chief Scientific Officer of Destiny Pharma #DEST FOLLOW explain the significance of world leading C. difficile scientists presenting landmark data on the ability of NTCD-M3 (one of its clinical assets) to colonise the gut after antibiotic administration at the prestigious Anaerobe 2022 Conference in Seattle, WA, US on Saturday, 30th July 2022.

Highlights

As previously reported, a Phase 2 clinical trial in patients suffering CDI demonstrated that administration of NTCD-M3 shortly after the use of antibiotics to treat the initial infection successfully reduced recurrence from 30% in placebo to 5% in treated patients. Patients received either vancomycin or metronidazole to treat the initial toxic C. difficile infection before receiving NTCD-M3 treatment.[1] Since the end of this trial, a new antibiotic, fidaxomicin, has been added to US clinical guidelines for treating CDI[2]. It is known that fidaxomicin3 resides for a longer period within the gut potentially inhibiting the colonisation by bacteria such as NTCD-M3. This latest study by the Microbiology Research Laboratory at the Edward Hines, Jr. VA Hospital in the US sought to address this question by monitoring the colonisation of NTCD-M3 in an established CDI model following administration of fidaxomicin.

In summary, this study conducted in the lab of the authors at the Edward Hines, Jr. VA Hospital, clearly demonstrated that NTCD-M3 was able to effectively colonise the gut following fidaxomicin administration indicating that NTCD-M3 would be effective in patients receiving this antibiotic as well as older antibiotics such as vancomycin and metronidazole.

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
Login or register to post comments

Recent Articles
Watchlist